Kallidinogenase for early recovery after stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether an experimental medication called human urinary kallidinogenase can help people recover better and faster after a recent stroke. The medication is given as an injection and is thought to improve blood flow to the brain, potentially helping with movement and daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had a stroke in the front part of the brain within the last 48 hours.
- Before this stroke, you were mostly independent (able to do daily activities without help).
- Your stroke symptoms are moderate, not too mild and not too severe, as measured by a standard stroke scale.
- You have not already received or plan to receive clot-busting medication or mechanical clot removal.
- You are not pregnant or breastfeeding, and don't plan to become pregnant for 90 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a medicine called human urinary kallidinogenase (which improves blood flow to the brain) to standard clot-busting treatment (reteplase) helps people recover better from an acute stroke. It's for patients who arrive at the hospital within 4.5 hours of symptom onset and meet specific safety criteria.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
This trial tests a drug called urinary kallidinogenase in people who have had a stroke and also have type 2 diabetes. The drug may help improve recovery after a stroke.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.